Cell Therapeutics, Inc. (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

1
Player Avatar LinuxCentOS (38.99) Submitted: 6/30/2009 6:23:35 PM : Outperform Start Price: $10.32 CTIC Score: -134.86

Drugs in pipeline.

Featured Broker Partners


Advertisement